Cargando…

Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls

OBJECTIVE: By the 1990s it became popular for women to use hormone therapy (HT) to ease menopause symptoms. Bioidentical estrogen and progesterone are supplements whose molecular structures are identical to what is made in the human body, while synthetic supplements are ones whose structures are not...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Zexian, Jiang, Xia, Li, Xiaoyu, Wells, Alan, Luo, Yuan, Neapolitan, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955567/
https://www.ncbi.nlm.nih.gov/pubmed/29768475
http://dx.doi.org/10.1371/journal.pone.0197064
_version_ 1783323743395774464
author Zeng, Zexian
Jiang, Xia
Li, Xiaoyu
Wells, Alan
Luo, Yuan
Neapolitan, Richard
author_facet Zeng, Zexian
Jiang, Xia
Li, Xiaoyu
Wells, Alan
Luo, Yuan
Neapolitan, Richard
author_sort Zeng, Zexian
collection PubMed
description OBJECTIVE: By the 1990s it became popular for women to use hormone therapy (HT) to ease menopause symptoms. Bioidentical estrogen and progesterone are supplements whose molecular structures are identical to what is made in the human body, while synthetic supplements are ones whose structures are not. After the Women’s Health Initiative found that the combined use of the synthetics conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) increased breast cancer risk, prescriptions for synthetic HT declined considerably. Since then there has been an increased interest in bioidentical HT; today there are a plethora of websites touting their benefits. However, no peer-reviewed articles support these claims. We performed a retrospective study with the objective of verifying the hypothesis that bioidentical HT is associated with decreased breast cancer risk than CEE & MPA. METHODS: We searched The Northwestern Medicine Enterprise Data Warehouse for women who initiated HT use after age 50. Women who did not take any HT drug after age 50 served as controls. Nine HT protocols were investigated for breast cancer risk. RESULTS: Significant results include CEE Alone is associated with decreased breast cancer risk (HR = 0.31), Other Synthetic Estrogen Alone is associated with increased breast cancer risk (HR = 1.49), Bioidentical Estrogen Alone is associated with decreased breast cancer risk(HR = 0.65), CEE & MPA is associated with reduced breast cancer risk (HR = 0.43), and CEE & MPA is associated with reduced breast cancer risk relative to Bioidentical Estrogen & Progesterone (HR = 0.25). DISCUSSION: Our results indicate CEE & MPA is superior to bioidentical HT as far as breast cancer risk. Furthermore, this combination is associated with decrease of breast cancer risk, contrary to previous findings. Additional retrospective studies are needed to confirm our results.
format Online
Article
Text
id pubmed-5955567
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59555672018-05-25 Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls Zeng, Zexian Jiang, Xia Li, Xiaoyu Wells, Alan Luo, Yuan Neapolitan, Richard PLoS One Research Article OBJECTIVE: By the 1990s it became popular for women to use hormone therapy (HT) to ease menopause symptoms. Bioidentical estrogen and progesterone are supplements whose molecular structures are identical to what is made in the human body, while synthetic supplements are ones whose structures are not. After the Women’s Health Initiative found that the combined use of the synthetics conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) increased breast cancer risk, prescriptions for synthetic HT declined considerably. Since then there has been an increased interest in bioidentical HT; today there are a plethora of websites touting their benefits. However, no peer-reviewed articles support these claims. We performed a retrospective study with the objective of verifying the hypothesis that bioidentical HT is associated with decreased breast cancer risk than CEE & MPA. METHODS: We searched The Northwestern Medicine Enterprise Data Warehouse for women who initiated HT use after age 50. Women who did not take any HT drug after age 50 served as controls. Nine HT protocols were investigated for breast cancer risk. RESULTS: Significant results include CEE Alone is associated with decreased breast cancer risk (HR = 0.31), Other Synthetic Estrogen Alone is associated with increased breast cancer risk (HR = 1.49), Bioidentical Estrogen Alone is associated with decreased breast cancer risk(HR = 0.65), CEE & MPA is associated with reduced breast cancer risk (HR = 0.43), and CEE & MPA is associated with reduced breast cancer risk relative to Bioidentical Estrogen & Progesterone (HR = 0.25). DISCUSSION: Our results indicate CEE & MPA is superior to bioidentical HT as far as breast cancer risk. Furthermore, this combination is associated with decrease of breast cancer risk, contrary to previous findings. Additional retrospective studies are needed to confirm our results. Public Library of Science 2018-05-16 /pmc/articles/PMC5955567/ /pubmed/29768475 http://dx.doi.org/10.1371/journal.pone.0197064 Text en © 2018 Zeng et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Zeng, Zexian
Jiang, Xia
Li, Xiaoyu
Wells, Alan
Luo, Yuan
Neapolitan, Richard
Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls
title Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls
title_full Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls
title_fullStr Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls
title_full_unstemmed Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls
title_short Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls
title_sort conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955567/
https://www.ncbi.nlm.nih.gov/pubmed/29768475
http://dx.doi.org/10.1371/journal.pone.0197064
work_keys_str_mv AT zengzexian conjugatedequineestrogenandmedroxyprogesteroneacetateareassociatedwithdecreasedriskofbreastcancerrelativetobioidenticalhormonetherapyandcontrols
AT jiangxia conjugatedequineestrogenandmedroxyprogesteroneacetateareassociatedwithdecreasedriskofbreastcancerrelativetobioidenticalhormonetherapyandcontrols
AT lixiaoyu conjugatedequineestrogenandmedroxyprogesteroneacetateareassociatedwithdecreasedriskofbreastcancerrelativetobioidenticalhormonetherapyandcontrols
AT wellsalan conjugatedequineestrogenandmedroxyprogesteroneacetateareassociatedwithdecreasedriskofbreastcancerrelativetobioidenticalhormonetherapyandcontrols
AT luoyuan conjugatedequineestrogenandmedroxyprogesteroneacetateareassociatedwithdecreasedriskofbreastcancerrelativetobioidenticalhormonetherapyandcontrols
AT neapolitanrichard conjugatedequineestrogenandmedroxyprogesteroneacetateareassociatedwithdecreasedriskofbreastcancerrelativetobioidenticalhormonetherapyandcontrols